| Home : PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial |
|
Dec 13
2016 |
PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial |
|
NEW YORK, NY--(Marketwired - December 12, 2016) - All of the pieces are starting to fall into place for PharmaCyte Biotech (OTCQB: PMCB) and its upcoming human clinical trial in advanced pancreatic cancer. Just one week after the U.S. Food and Drug Administration (FDA) granted the biotech a pre-IND (Investigational New Drug) meeting to discuss the company's clinical trial, PharmaCyte qualified to use its multi-million dollar "at-the-market" funding arrangement with Chardan Capital in order to enroll every single patient into its upcoming clinical trial. |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2182448&sourceType=3 |
| |
|
Related News
|
» Bravada Announces Equity Financing
» Inter Pipeline to Acquire Remaining Interest in the Cold Lake Pipeline System and Announces New Oil Sands Transportation Agreement
|
